医学
维多利祖马布
克罗恩病
炎症性肠病
疾病
期限(时间)
立场文件
胃肠病学
内科学
重症监护医学
病理
物理
量子力学
作者
Edouard Louis,Michal Litkiewicz,Christian Agboton,Alessandro Armuzzi
摘要
Several biologics are available for the treatment of moderate to severe Crohn's disease, but data to optimize their use are scarce. Vedolizumab (VDZ) is a gut-selective anti-lymphocyte trafficking monoclonal antibody that was approved in 2014 for the treatment of moderate to severe Crohn's disease. Based on real-world evidence, a model was developed to examine the effect of VDZ's position in the treatment sequence on clinical outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI